文献速递乳腺PET

分子乳腺成像上的背景实质摄取与乳腺癌风险:一项队列研究

Background Parenchymal Uptake on Molecular Breast Imaging and Breast Cancer Risk: A Cohort Study.
PubMed 文献 · AJR Am J Roentgenol · 2021-03-03

该回顾性队列纳入2004至2015年接受分子乳腺成像且无乳腺癌史的2992名女性,中位随访7.3年。背景实质摄取升高与乳腺癌风险升高相关(HR 2.39),该关联在绝经后女性中显著(HR 3.50)而绝经前不显著。在绝经后女性中,背景实质摄取联合Gail或BCSC风险模型可改善对浸润性癌的判别能力。

要点

  • 分子乳腺成像上背景实质摄取升高是乳腺癌独立危险因素,绝经后女性关联最强。
  • 绝经后致密乳腺且背景实质摄取升高者5年绝对风险为8.1%,低摄取者为2.8%。
  • 绝经后女性中,背景实质摄取联合Gail或BCSC模型可改善浸润性癌判别能力。

核心结论

  • 分子乳腺成像上的背景实质摄取是乳腺癌的独立危险因素,在绝经后致密乳腺女性中关联最强。
  • 在绝经后女性中,背景实质摄取联合Gail模型或乳腺癌症监测联盟模型可提供增量判别能力。

研究设计与样本

  • 回顾性队列研究,纳入2004至2015年接受分子乳腺成像且无乳腺癌史的女性2992名,平均年龄56.3岁(SD 10.6岁)。
  • 放射科医生在不知晓未来乳腺癌诊断的情况下,将基线分子乳腺成像上的背景实质摄取评估为低(无光子摄取或极少)或升高(轻度、中度或明显)。
  • 采用多变量Cox比例风险模型分析背景实质摄取与乳腺癌诊断时间的关联,并计算研究亚组的5年绝对风险。

关键影像表现/征象

  • 背景实质摄取升高与乳腺癌风险升高相关(HR 2.39;95%CI 1.68-3.41;p≤.001)。
  • 该关联在绝经后女性中仍存在(HR 3.50;95%CI 2.31-5.31;p<.001),但在绝经前女性中不显著(HR 1.29;95%CI 0.72-2.32;p=.39)。

诊断标准与关键数值

  • 背景实质摄取升高女性5年乳腺癌绝对风险为4.3%(95%CI 2.9-5.7%),低摄取女性为2.5%(95%CI 1.8-3.1%)。
  • 绝经后致密乳腺且背景实质摄取升高女性5年绝对风险为8.1%(95%CI 4.3-11.8%),低摄取者为2.8%(95%CI 1.8-3.8%)。
  • 绝经后女性中,背景实质摄取联合Gail风险评分较单用Gail评分改善浸润性癌判别能力(C统计量65.1 vs 59.1;p=.04)。
  • 绝经后女性中,背景实质摄取联合乳腺癌症监测联盟风险评分较单用该评分改善浸润性癌判别能力(C统计量66.4 vs 60.4;p=.04)。

临床应用与阅片要点

  • 分子乳腺成像上观察到背景实质摄取升高可能识别出致密乳腺女性中从补充筛查或预防措施中获益最大的亚组。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

BACKGROUND. Background parenchymal uptake (BPU) on molecular breast imaging (MBI) was identified in a case-control study as a breast cancer risk factor beyond mammographic density. To our knowledge, this finding has not yet been confirmed in a cohort study. OBJECTIVE. The objectives of this study were to examine the association of BPU with breast cancer and to estimate the absolute risk and discriminatory accuracy of BPU in a cohort study. METHODS. A retrospective cohort was established that included women without a history of breast cancer who underwent MBI from 2004 to 2015. Radiologists who were blinded to future breast cancer diagnoses assessed BPU on baseline MBI examinations as low (photopenic or minimal) or elevated (mild, moderate, or marked). Associations of BPU with breast cancer were estimated using multivariable Cox proportional hazards models of the time to diagnosis. The 5-year absolute risk was calculated for study subgroups. The discriminatory accuracy of BPU was also assessed. RESULTS. Among 2992 women (mean age, 56.3 years; SD, 10.6 years) who underwent MBI, breast cancer events occurred in 144 women (median follow-up, 7.3 years). Median time to diagnosis after MBI was 4.2 years (range, 0.5-11.6 years). Elevated BPU was associated with a greater breast cancer risk (hazard ratio [HR], 2.39; 95% CI, 1.68-3.41; p ≤ .001). This association remained in postmenopausal women (HR, 3.50; 95% CI, 2.31-5.31; p < .001) but was not significant in premenopausal women (HR, 1.29; 95% CI, 0.72-2.32; p = .39). The 5-year absolute risk of breast cancer was 4.3% (95% CI, 2.9-5.7%) for women with elevated BPU versus 2.5% (95% CI, 1.8-3.1%) for those with low BPU. Postmenopausal women with dense breasts and elevated BPU had a 5-year absolute risk of 8.1% (95% CI, 4.3-11.8%) versus 2.8% (1.8-3.8%) for those with low BPU. Among postmenopausal women, discriminatory accuracy for invasive cancer was improved with the addition of BPU versus use of the Gail risk score alone (C statistic, 65.1 vs 59.1; p = .04) or use of the Breast Cancer Surveillance Consortium risk score alone (C statistic, 66.4 vs 60.4; p = .04). CONCLUSION. BPU on MBI is an independent risk factor for breast cancer, with the strongest association observed among postmenopausal women with dense breasts. In postmenopausal women, BPU provides incremental discrimination in predicting breast cancer when combined with either the Gail model or the Breast Cancer Surveillance Consortium model. CLINICAL IMPACT. Observation of elevated BPU on MBI may identify a subset of women with dense breasts who would benefit most from supplemental screening or preventive options.

来源:AJR Am J Roentgenol,查看原文。版权归原作者所有。

引用

  1. Hruska CB, Geske JR, Conners AL, et al. Background Parenchymal Uptake on Molecular Breast Imaging and Breast Cancer Risk: A Cohort Study. AJR Am J Roentgenol. 2021. PMID: 32755210. doi:10.2214/AJR.20.23854

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。